Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Childhood Obesity, Morbid Obesity
Interventions: Transcriptome profiling; Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 2 Years to 20 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 2
States / cities: Boston, New York • New York, New York

Conditions: Cognitive Impairment
Interventions: Single Dose of VU319, Single Dose Placebo, Fed State, Fasted State, Dose Escalation of VU319, Placebo Dose Escalation; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gout, Food-drug Interaction
Interventions: ABP-671; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Anxiety, Literacy, Satisfaction, Patient
Interventions: Educational Video; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Interventions: Abemaciclib,; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Secondary Hyperparathyroidism, Hypocalcemia
Interventions: Calcitriol; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Spine, Low Back Pain, Neck Pain
Interventions: Massage, Talk-based therapy; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obesity
Interventions: Intervention Group, Control Group; Behavioral
Lead sponsor: BETH COMERFORD; Other
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: insulin aspart, insulin detemir; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Weight Loss
Interventions: Portion-Controlled Meals, Low-Calorie Diet, Intermittent Very-Low Calorie Diet; Dietary Supplement · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy
Interventions: cefprozil, Cefzil®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: amoxicillin 400mg + clovalunic acid 57.5mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Out-of-hospital Cardiac Arrest
Interventions: Rapid infusion of 2 liters of 4oC normal saline, Rapid infusion of cold normal saline; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Cefprozil for oral suspension 250 mg/5 mL, CEFZIL® for Oral Suspension 250 mg/5mL; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Gestational Diabetes
Interventions: Glucose Monitoring; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine Extended Release, Olanzapine Immediate Release; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more

Conditions: Healthy Volunteers
Interventions: Naproxen, PL 3100; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy, Renal Impairment
Interventions: Calderasib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Chicago, Illinois

Conditions: Alzheimer's Disease, Obesity, Diabetes Mellitus
Interventions: Boost (R) 5-2 diet, Healthy Living Diet; Other
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene, midazolam; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Pain
Interventions: 14C-VX-993; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: COVID-19, Lung Inflammation
Interventions: Regadenoson, Placebo Control; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Stenosis, Coronary Artery Disease
Interventions: IoNIR Ridaforolimus-Eluting Coronary Stent System; Device
Lead sponsor: Medinol Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Roslyn, New York

Search by objective public record fields.

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

Putative Cognitive Enhancer VU319

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

Effect of an Educational Nail Biopsy Video on Pre-operative Anxiety, Health Literacy, and Patient Satisfaction

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions

Differences in Mechanistic Measures (Oxytocin and Cortisol) of Therapeutic Alliance Between A Talk-Based Therapy and Soft-Tissue Mobilization in Individuals With Chronic Spinal Pain

Fruit and Vegetable Prescription Program

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

KU Alternate Meal Energy Level Study

Cefprozil 500 mg Tablets Under Fed Conditions

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions

Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest

Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting

Daily Versus Every Other Day Glucose Monitoring in Gestational Diabetes Mellitus

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults

A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)

Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

Treat COVID-19 Patients With Regadenoson

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System